---
title: "If You Invested $1000 In Ascendis Pharma Stock 10 Years Ago, You Would Have This Much Today"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297063733.md"
description: "Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past decade with an average annual return of 30.07%, significantly exceeding market growth by 16.69% on an annualized basis. With a current market capitalization of $16.63 billion and a stock price of $253.50, an initial investment of $1,000 made ten years ago would now be worth approximately $14,049.83, illustrating the power of compounded returns."
datetime: "2026-08-26T14:45:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297063733.md)
  - [en](https://longbridge.com/en/news/297063733.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297063733.md)
generator: "portal-rs"
---

# If You Invested $1000 In Ascendis Pharma Stock 10 Years Ago, You Would Have This Much Today

Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 10 years by 16.69% on an annualized basis producing an average annual return of 30.07%. Currently, Ascendis Pharma has a market capitalization of $16.63 billion.

**Buying $1000 In ASND:** If an investor had bought $1000 of ASND stock 10 years ago, it would be worth **$14,049.83** today based on a price of $253.50 for ASND at the time of writing.

### Ascendis Pharma’s Performance Over Last 10 Years

![comp_fig](https://imageproxy.pbkrs.com/https://cdn.benzinga.com/files/images/story/2026/08/26/f0313fdea1bb25289cbcce2efbb7f5be.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg)

Finally -- what’s the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.

*This article was generated by Benzinga's automated content engine and reviewed by an editor.*

### Related Stocks

- [ASND.US](https://longbridge.com/en/quote/ASND.US.md)

## Related News & Research

- [Ascendis Pharma (ASND) On Profitability, The Valuation Narrative Still Points To Upside](https://longbridge.com/en/news/296831532.md)
- [Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026 | ASND Stock News](https://longbridge.com/en/news/296951291.md)
- [Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes](https://longbridge.com/en/news/297515082.md)
- [This Ascendis Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday](https://longbridge.com/en/news/297205620.md)
- [Ascendis Pharma Files Strong Interim Q2 2026 Results on Form 6-K](https://longbridge.com/en/news/295797900.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**